Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma 3Multiple Myeloma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 14Nivolumab 9Specimen Handling 4Magnetic Resonance Spectroscopy 4fludarabine 3atezolizumab 3Ipilimumab 3Drug Therapy 3Cyclophosphamide 3epacadostat 2entrectinib 2durvalumab 2X-Rays 2Sirolimus 2Radiotherapy 2Radiation 2Methods 2Interleukin-2 2Injections 2CTLA-4 Antigen 2Blood Specimen Collection 2Biopsy 2zimberelimab 1vocimagene amiretrorepvec 1varlilumab 1utomilumab 1ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × marizomib × Lymphoid × Clear all
NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

Phase 1 Completed
22 enrolled
DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡